News

OCRF Research Sheds New Light on Ovarian Cancer Metastasis

(July 21, 2014) According to research funded in part by OCRF, circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs. This new finding, supported in part by an OCRF Program Project Development... 

Phil and Judy Messing: OCRF Partners in Science

When Phil and Judy Messing lost their daughter Carol to ovarian cancer in 2008, they knew they wanted to honor her memory by supporting ovarian cancer research. They searched for an organization that would help them feel connected and involved, and found that in OCRF. They chose to participate in our... 

OCRF Research Shows ARID1A is Tumor Suppressor Gene

Bin Guan, PhD (July 8, 2014) Frequent mutations in the ARID1A gene have been previously discovered in ovarian endometrioid and clear-cell cancers.  Now research supported by OCRF has provided direct evidence that it is an authentic tumor suppressor gene using a mouse model.  OCRF Ann Schreiber Mentored... 

Q&A with OCRF Grantee John Weroha, MD, PhD

Q&A with John Weroha, MD, PhD 2014 Liz Tilberis Early Career Award Mayo Clinic               Were you always in interested in science?  By the time I was in high school I knew I wanted to have a career in biology, but I think my interest actually started earlier. ... 

No Link Between Fertility Drugs and Breast, Ovarian and Uterine Cancers

(July 1, 2014)  There is “little evidence” that the use of conventional fertility hormones used for ovarian stimulation in the treatment of infertility increases the long-term risk of breast and gynecological cancers, according to the results of a significant 30-year follow-up study. However,... 

Palliative Care at Time of Cancer Diagnosis Improves Survival

(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis improves survival. A randomized trial of palliative oncology care in 207 patients with advanced cancer and their... 

Gemcitabine, Carboplatin, and Bevacizumab Extend PFS

(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published... 

Webinar Highlights Research News from ASCO

On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research  news that was presented at 2014′s medical meetings.  In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the... 

ASCO News: Two New Drugs Show Promise for Recurrent Ovarian Cancer

(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this... 

FDA Seeking Comments on Olaparib by June 11

The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells.  AstraZeneca, the company that manufactures the...